Amgen lines up expansion to Otezla's $13B franchise; China OKs 'breakthrough' use of PD-1
Amgen’s $13 billion drug Otezla is being lined up for an add-on OK as rivals at Bristol Myers circle in with a rival therapy. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
